Everything below concerns acetylated peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Early work on the study of the chemistry of rutherfordium focused on gas thermochromatography and measurement of relative deposition temperature adsorption curves. The initial work was carried out at Dubna in an attempt to reaffirm their discovery of the element. Recent work is more reliable regarding the identification of the parent rutherfordium radioisotopes. The isotope 261mRf has been used for these studies, though the long-lived 267Rf (produced in the decay chain of 291Lv, 287Fl, and 283Cn) may be advantageous for future experiments. The experiments relied on the expectation that rutherfordium would be a 6d element in group 4 and should therefore form a volatile molecular tetrachloride, that would be tetrahedral in shape. Rutherfordium(IV) chloride is more volatile than its lighter homologue hafnium(IV) chloride (HfCl4) because its bonds are more covalent. A series of experiments confirmed that rutherfordium behaves as a typical member of group 4, forming a tetravalent chloride (RfCl4) and bromide (RfBr4) as well as an oxychloride (RfOCl2). A decreased volatility was observed for RfCl4 when potassium chloride is provided as the solid phase instead of gas, highly indicative of the formation of nonvolatile K2RfCl6 mixed salt.
After concluding that continued hostilities would risk economic calamity, Donald Trump signed a memorandum of understanding (MOU) on behalf of the United States during a ceremony at the Palace of Versailles on 17 June 2026. The signing followed an earlier, digital signing of the MOU by the foreign ministers of the two principal belligerents. In the MOU, the United States and Iran agreed to suspend hostilities for 60 days and to establish a framework for a permanent peace under which the US would make major financial and political concessions to the Islamic Republic of Iran. The memorandum began to collapse on 7 July 2026, when Iranian forces attacked three commercial vessels in the Strait of Hormuz, including a Qatari LNG tanker, setting it ablaze and damaging other ships. Iranian officials told The New York Times that internal inquiries traced the decision to Hossein Taeb, head of the Basij and former Revolutionary Guards’ intelligence agency chief. The United States responded with airstrikes on Iranian territory within a day of the ship attacks, effectively ending the ceasefire and resuming hostilities between the two countries.
== Alternatives == Many forms of artificial leather have been developed, usually involving polyurethane or vinyl coatings applied to a cloth backing. Many names and brands for such artificial leathers exist, including "pleather", a portmanteau of "plastic leather", and the brand name Naugahyde. Another alternative is cultured leather which is lab-grown using cell-culture methods, mushroom-based materials and gelatin-based textile made by upcycling meat industry waste. Leather made of fungi or mushroom-based materials are completely biodegradable.
Sources: en.wikipedia.org
==== Anglo-American ==== Richard Steiff, the creator of the teddy bear, made the toy in 1902 under Margarete Steiff's felt goods company. The toys were brought to the US and gained mass popularity after a newspaper told the story of Theodore Roosevelt refusing to shoot a black bear cub tied to a tree. The fictional character Winnie-the-Pooh was named after Winnipeg, a female cub that lived at the London Zoo from 1915 until her death in 1934. A cub, who in the spring of 1950 was caught in the Capitan Gap Fire, was made into the living representative of Smokey Bear, the mascot of the United States Forest Service. Terrible Ted was a de-toothed and de-clawed bear who was forced to perform as a pro wrestler and whose "career" lasted from the 1950s to the 1970s. Clark's Bears, previously named Clark's Trading Post, is a visitor attraction in Lincoln, New Hampshire known for its trained bear shows since 1949. The American black bear is the mascot of the University of Maine and Baylor University, the latter of which houses two live bears on campus.
Harrison's Principles of Internal Medicine is an American textbook of internal medicine. First published in 1950, it is in its 22nd edition (published in 2025 by McGraw-Hill Professional) and comes in two volumes. Although it is aimed at all members of the medical profession, it is mainly used by internists and junior doctors in this field, as well as medical students. It is widely regarded as one of the most authoritative books on internal medicine and has been described as the "most recognized book in all of medicine." The work is named after Tinsley R. Harrison of Birmingham, Alabama, who served as editor-in-chief of the first five editions and established the format of the work: a strong basis of clinical medicine interwoven with an understanding of pathophysiology.
=== Alcohol use === Lifestyle factors, such as substance use or adiposity, can play a detrimental role in the quality of the semen. One study examining the consequences of alcohol consumption and its effect on semen quality concluded that alcohol intake can lead to a negative effect on semen volume in daily alcohol consumers. However, occasional or moderate use of alcohol was observed to not have an adverse effect on the semen.
Sources: en.wikipedia.org
=== Classical Greek medicine === Robin Fåhræus (a Swedish physician who devised the erythrocyte sedimentation rate) suggested that the Ancient Greek system of humorism, wherein the body was thought to contain four distinct bodily fluids (associated with different temperaments), were based upon the observation of blood clotting in a transparent container. When blood is drawn in a glass container and left undisturbed for about an hour, four different layers can be seen. A dark clot forms at the bottom (the "black bile"). Above the clot is a layer of red blood cells (the "blood"). Above this is a whitish layer of white blood cells (the "phlegm"). The top layer is clear yellow serum (the "yellow bile"). In general, Greek thinkers believed that blood was made from food. Plato and Aristotle are two important sources of evidence for this view, but it dates back to Homer's Iliad. Plato thought that fire in our bellies transformed food into blood, and that the movements of air in the body as we breathed carried the fire as it transformed our food into blood. Aristotle believed that food is concocted into blood in the heart and transformed into our body's matter.
By doing tandem mass spectrometry in time, the separation is accomplished with ions trapped in the same place, with multiple separation steps taking place over time. A quadrupole ion trap or Fourier transform ion cyclotron resonance instrument can be used for such an analysis. Trapping instruments can perform multiple steps of analysis, which is sometimes referred to as MSn (MS to the n). Often the number of steps, n, is not indicated, but occasionally the value is specified; for example MS3 indicates three stages of separation. Tandem in time MS instruments do not use the modes described next, but typically collect all of the information from a precursor ion scan and a parent ion scan of the entire spectrum. Each instrumental configuration utilizes a unique mode of mass identification.
According to James B. Harrod humankind first developed religious and spiritual beliefs during the Middle Paleolithic or Upper Paleolithic. Controversial scholars of prehistoric religion and anthropology, James Harrod and Vincent W. Fallio, have recently proposed that religion and spirituality (and art) may have first arisen in Pre-Paleolithic chimpanzees or Early Lower Paleolithic (Oldowan) societies. According to Fallio, the common ancestor of chimpanzees and humans experienced altered states of consciousness and partook in ritual, and ritual was used in their societies to strengthen social bonding and group cohesion. Middle Paleolithic humans' use of burials at sites such as Krapina, Croatia (c. 130,000 BP) and Qafzeh, Israel (c. 100,000 BP) have led some anthropologists and archaeologists, such as Philip Lieberman, to believe that Middle Paleolithic humans may have possessed a belief in an afterlife and a "concern for the dead that transcends daily life". Cut marks on Neanderthal bones from various sites, such as Combe-Grenal and Abri Moula in France, suggest that the Neanderthals—like some contemporary human cultures—may have practiced ritual defleshing for (presumably) religious reasons. According to recent archaeological findings from Homo heidelbergensis sites in Atapuerca, humans may have begun burying their dead much earlier, during the late Lower Paleolithic; but this theory is widely questioned in the scientific community.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.